 UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 GLOBE NEWSWIRE -- Merus N.V. Nasdaq: MRUS, a clinical-stage oncology company developing innovative, full-length multispecific antibodies Biclonics and Triclonics, today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET. 